UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside

Cancer, 2018-06, Vol.124 (12), p.2498-2506

2018

Volltextzugriff (PDF)

CARM1 Methylates Chromatin Remodeling Factor BAF155 to Enhance Tumor Progression and Metastasis

Cancer cell, 2014-01, Vol.25 (1), p.21-36

2014

Volltextzugriff (PDF)

BAF155 methylation drives metastasis by hijacking super-enhancers and subverting anti-tumor immunity

Nucleic acids research, 2021-12, Vol.49 (21), p.12211-12233

2021

Volltextzugriff (PDF)

Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression

Cancer discovery, 2016-05, Vol.6 (5), p.516-531

2016

Volltextzugriff (PDF)

Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model

Oncoimmunology, 2019-03, Vol.8 (3), p.1553477-1553477

2019

Volltextzugriff (PDF)

CARM1 Methylates Chromatin Remodeling Factor BAF155 to Enhance Tumor Progression and Metastasis

Cancer cell, 2016-07, Vol.30 (1), p.179-180

2016

Volltextzugriff (PDF)

Identification of estrogen receptor dimer selective ligands reveals growth-inhibitory effects on cells that co-express ERα and ERβ

PloS one, 2012-02, Vol.7 (2), p.e30993-e30993

2012

Volltextzugriff (PDF)

Results from a prospective longitudinal survey of employment and work outcomes in newly diagnosed cancer patients during and after curative‐intent chemotherapy: A Wisconsin Oncology Network study

Cancer, 2021-03, Vol.127 (5), p.801-808

2021

Volltextzugriff (PDF)

Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer

Molecular cancer therapeutics, 2014-05, Vol.13 (5), p.1356-1368

2014

Volltextzugriff (PDF)

A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)

Cancer medicine (Malden, MA), 2022-11, Vol.11 (21), p.3969-3981

2022

Volltextzugriff (PDF)

Identification of Selective Lead Compounds for Treatment of High-Ploidy Breast Cancer

Molecular cancer therapeutics, 2016-01, Vol.15 (1), p.48-59

2016

Volltextzugriff (PDF)

Abbreviated endocrine therapy duration for low estrogen receptor‐positive breast cancer: The counter to extended endocrine therapy

Cancer, 2022-05, Vol.128 (9), p.1724-1726

2022

Volltextzugriff (PDF)

A phenocopy signature of TP53 loss predicts response to chemotherapy

NPJ precision oncology, 2024-10, Vol.8 (1), p.220-10, Article 220

2024

Volltextzugriff (PDF)

Role of the androgen receptor in triple-negative breast cancer

Clinical advances in hematology & oncology, 2016-03, Vol.14 (3), p.186-193

2016

Volltextzugriff (PDF)

BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations

Radiology, 2019-06, Vol.291 (3), p.554-569

2019

Volltextzugriff (PDF)

Tumor-on-a-chip: a microfluidic model to study cell response to environmental gradients

Lab on a chip, 2019-10, Vol.19 (2), p.3461-3471

2019

Volltextzugriff (PDF)

The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma Patients

The American journal of pathology, 2018-03, Vol.188 (3), p.559-573

2018

Volltextzugriff (PDF)

Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel

Science translational medicine, 2021-09, Vol.13 (610), p.eabd4811

2021

Volltextzugriff (PDF)

Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?

Clinical breast cancer, 2023-12, Vol.23 (8), p.813-824

2023

Volltextzugriff (PDF)

Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS-STING Signaling in Triple-Negative Breast Cancer

Molecular cancer therapeutics, 2021-12, Vol.20 (12), p.2553-2567

2021

Volltextzugriff (PDF)

Advances in the Treatment of Early-Stage HER2-Positive Breast Cancer

Clinical advances in hematology & oncology, 2020-08, Vol.18 (8), p.482-492

2020

Volltextzugriff (PDF)

Concurrent Radiation and Modern Systemic Therapies for Breast Cancer: An Ever-Expanding Frontier

Clinical breast cancer, 2021-04, Vol.21 (2), p.120-127

2021

Volltextzugriff (PDF)

Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer

Clinical cancer research, 2016-06, Vol.22 (11), p.2659-2667

2016

Volltextzugriff (PDF)

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

Clinical cancer research, 2022-06, Vol.28 (11), p.2257-2269

2022

Volltextzugriff (PDF)

1 – 25 von 105

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(98)
Mit Volltextzugriff
(86)

Publikationsform

Artikel
(105)

Sprache

Englisch
(105)

Erscheinungsjahr

n.n

Thema

Science & Technology
(59)
Life Sciences & Biomedicine
(57)
Humans
(53)
Oncology
(45)
Female
(42)
Breast Cancer
(23)
Middle Aged
(23)
Aged
(19)
Adult
(16)
Breast Neoplasms - Drug Therapy
(15)
Male
(14)
Cancer
(13)
Tumors
(13)
Breast Neoplasms - Genetics
(12)
Breast Neoplasms - Pathology
(10)
Aged, 80 And Over
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
Breast Neoplasms - Metabolism
(9)
Cancer Therapies
(9)
Chemotherapy
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside

CARM1 Methylates Chromatin Remodeling Factor BAF155 to Enhance Tumor Progression and Metastasis

BAF155 methylation drives metastasis by hijacking super-enhancers and subverting anti-tumor immunity

Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression

Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model

CARM1 Methylates Chromatin Remodeling Factor BAF155 to Enhance Tumor Progression and Metastasis

Identification of estrogen receptor dimer selective ligands reveals growth-inhibitory effects on cells that co-express ERα and ERβ

Results from a prospective longitudinal survey of employment and work outcomes in newly diagnosed cancer patients during and after curative‐intent chemotherapy: A Wisconsin Oncology Network study

Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer

A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)

Identification of Selective Lead Compounds for Treatment of High-Ploidy Breast Cancer

Abbreviated endocrine therapy duration for low estrogen receptor‐positive breast cancer: The counter to extended endocrine therapy

A phenocopy signature of TP53 loss predicts response to chemotherapy

Role of the androgen receptor in triple-negative breast cancer

BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations

Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial

Tumor-on-a-chip: a microfluidic model to study cell response to environmental gradients

The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma Patients

Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel

Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?

Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS-STING Signaling in Triple-Negative Breast Cancer

Advances in the Treatment of Early-Stage HER2-Positive Breast Cancer

Concurrent Radiation and Modern Systemic Therapies for Breast Cancer: An Ever-Expanding Frontier

Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

Suchergebnisse filtern